VolitionRx Limited - SIC # 3850 -

Ticker Exchange SIC # Website Latest Ticker
VNRX NYSE American 3850 www.volition.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for VolitionRx Limited

VolitionRX Ltd (VNRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances - Apr 1st, 2025 7:03 am
VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update - Mar 31st, 2025 8:05 pm
Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025 - Mar 28th, 2025 12:00 pm
Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025 - Mar 27th, 2025 12:30 pm
VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering - Mar 26th, 2025 12:00 pm
VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update - Mar 25th, 2025 1:30 pm
Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry - Mar 21st, 2025 12:30 pm
Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer - Mar 20th, 2025 12:30 pm
Volition Proudly Sponsors the 44th ISICEM Congress - Mar 17th, 2025 12:30 pm
Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems - Mar 13th, 2025 12:30 pm
Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test - Mar 11th, 2025 12:30 pm
VNRX: Additional clinical papers & company webinars provide insights to Volition’s progress. Nu.Q Discover biomarkers selected for clinical trial. Management continues to focus on signing licensing deals for Capture-PCR & Nu.Q NETs - Mar 5th, 2025 9:21 am
Volition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time - Mar 4th, 2025 1:30 pm
Volition Showcases Nu.Q® Vet Cancer Test at the 97th WVC Annual Conference - Feb 28th, 2025 1:30 pm
Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis - Feb 6th, 2025 1:30 pm
Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025 - Feb 5th, 2025 2:15 pm
Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis - Jan 30th, 2025 1:30 pm
Volition Issues Business Review 2024 - Jan 8th, 2025 1:30 pm
VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants - Dec 12th, 2024 1:00 pm
Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening - Dec 10th, 2024 1:00 pm